The present research was performed to monitor the anti-rheumatoid action of Consciousness Energy Healing based DMEM medium using synovial sarcoma cell line, SW982. The study included the evaluation of bone health potential using inflammatory parameter, IL-8. The test item (DMEM medium) was divided into three parts, first part received a one-time Consciousness Energy Healing Treatment by a renowned Biofield Energy Healer, Mahendra Kumar Trivedi and was labeled as the one-time Biofield Energy Treated (BT-I) DMEM, while second part received the two-times the Biofield Energy Treatment and is denoted as BT-II DMEM. The third part did not receive any treatment and defined as the untreated DMEM group. Cell viability assay using MTT method showed that the cell viability of SW982 cells was 113.8% and 88.3% in the BT-I and BT-II groups, respectively. The BT-I group demonstrated significant (p≤0.001) inhibition of IL-8 by 27.74%, while BT-II group also showed a significant (p≤0.001) inhibition of IL-8 by 45.66% as compared to the untreated DMEM group. In conclusion, the data suggested that the Consciousness Energy Healing Treatment significantly inhibited the pro-inflammatory cytokine (IL-8) that showed anti-rheumatic action and can also be used in other bone and inflammatory disorders such as osteoporosis, Paget’s disease of bone, rickets, deformed bones, osteomalacia, osteoma, stress, aging, bone loss, and fractures along with autoimmune disorders and overall quality of life.
{"title":"Impact of Biofield Energy Healing Treatment: Evaluation of AntiRheumatoid Activity Using Synovial Sarcoma Cell Line (SW982)","authors":"M. Trivedi, S. Jana","doi":"10.36876/smmd.1034","DOIUrl":"https://doi.org/10.36876/smmd.1034","url":null,"abstract":"The present research was performed to monitor the anti-rheumatoid action of Consciousness Energy Healing based DMEM medium using synovial sarcoma cell line, SW982. The study included the evaluation of bone health potential using inflammatory parameter, IL-8. The test item (DMEM medium) was divided into three parts, first part received a one-time Consciousness Energy Healing Treatment by a renowned Biofield Energy Healer, Mahendra Kumar Trivedi and was labeled as the one-time Biofield Energy Treated (BT-I) DMEM, while second part received the two-times the Biofield Energy Treatment and is denoted as BT-II DMEM. The third part did not receive any treatment and defined as the untreated DMEM group. Cell viability assay using MTT method showed that the cell viability of SW982 cells was 113.8% and 88.3% in the BT-I and BT-II groups, respectively. The BT-I group demonstrated significant (p≤0.001) inhibition of IL-8 by 27.74%, while BT-II group also showed a significant (p≤0.001) inhibition of IL-8 by 45.66% as compared to the untreated DMEM group. In conclusion, the data suggested that the Consciousness Energy Healing Treatment significantly inhibited the pro-inflammatory cytokine (IL-8) that showed anti-rheumatic action and can also be used in other bone and inflammatory disorders such as osteoporosis, Paget’s disease of bone, rickets, deformed bones, osteomalacia, osteoma, stress, aging, bone loss, and fractures along with autoimmune disorders and overall quality of life.","PeriodicalId":132433,"journal":{"name":"SM Musculoskeletal Disorders","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127057900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Moustapha, Kane Baïdy Sy, Salissou Garba Mahaman, Sarr Lamine, D. Coumba, Akpo L. Geraud, D. A. Badara, Diallo Saidou, Ndongo Souhaibou, Pouye Abdoulaye
Exostosis is a benign tumour corresponding to a well-differentiated bone excrescence, produced by a germinal cartilage cap during growth [1,2]. It is most often sporadic, but it can also be part of an autosomal dominant, multiple exostosis disease known as Bessel-Hagen disease [1]. Exostosis, especially in its solitary form, represents the most frequent benign tumour (20 to 50% of benign bone tumours and 10 to 15% of all bone tumours) [1]. The multiple exostosis disease is a rare disease first described by Boyer in 1814 [3-5]. It is mainly reported in Western literature where its prevalence is estimated at 1/50,000 [3,5] and, to a lesser extent, in North Africa [6,7]. This prevalence has not been determined in the African population. However, work has been carried out on the disease in North Africa and sub-Saharan Africa [3-12]. Studies evaluating family forms of the disease were mainly carried out in the Western literature [12-18]. In sub-Saharan Africa, reported cases are apparently sporadic. The objective of this work was to study the epidemiological, diagnostic and therapeutic aspects of familial forms of multiple exostosis disease.
{"title":"Multiple Exostosis Disease: Study of Three Senegalese Families","authors":"N. Moustapha, Kane Baïdy Sy, Salissou Garba Mahaman, Sarr Lamine, D. Coumba, Akpo L. Geraud, D. A. Badara, Diallo Saidou, Ndongo Souhaibou, Pouye Abdoulaye","doi":"10.36876/smmd.1032","DOIUrl":"https://doi.org/10.36876/smmd.1032","url":null,"abstract":"Exostosis is a benign tumour corresponding to a well-differentiated bone excrescence, produced by a germinal cartilage cap during growth [1,2]. It is most often sporadic, but it can also be part of an autosomal dominant, multiple exostosis disease known as Bessel-Hagen disease [1]. Exostosis, especially in its solitary form, represents the most frequent benign tumour (20 to 50% of benign bone tumours and 10 to 15% of all bone tumours) [1]. The multiple exostosis disease is a rare disease first described by Boyer in 1814 [3-5]. It is mainly reported in Western literature where its prevalence is estimated at 1/50,000 [3,5] and, to a lesser extent, in North Africa [6,7]. This prevalence has not been determined in the African population. However, work has been carried out on the disease in North Africa and sub-Saharan Africa [3-12]. Studies evaluating family forms of the disease were mainly carried out in the Western literature [12-18]. In sub-Saharan Africa, reported cases are apparently sporadic. The objective of this work was to study the epidemiological, diagnostic and therapeutic aspects of familial forms of multiple exostosis disease.","PeriodicalId":132433,"journal":{"name":"SM Musculoskeletal Disorders","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126815060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Plantar fibromatosis of the foot is a rare benign, hyperproliferative, and local aggressive disease of the plantar aponeurosis (i.e. fascia) (Figure 1A) of unknown etiology and included among the extra-abdominal desmoids tumors, this entity was first described in 1894 bythe German physician Georg Ledderhose (1855-1925), and it is accompanied by a high recurrence rate [1-3]. Regarding etiology, it has been described to be most frequent in patients with diabetes, low body weight, epilepsy, alcohol abuse, and smoking, and a familial history in up to 19.1% of cases is observed as well [2,4]. Occurrence is observed at all ages ranging from 2 to 83 years (N=178), but especially in the 4th and 5th decade of life in the absence of significant sex-related differences (51.7% male vs. 48.3% female in 178 patients), and bilateral involvement is reported to be 20-50% of cases [2,4]. It can be associated in 5-21.3% of cases with the palmar fibromatosis of the hand (Figure 2A-D) first described quite earlier in 1831by the French physician Baron Guillaume Dupuytren (17771835) which can also be associated with the fibrous subcutaneous nodules (i.e. knuckle pads) upon the proximal interphalangeal finger joints (Figure 3) first described in1904 by the British physician SirArchibald Edward Garrod (1857-1936), and in 1-3% of cases with the penile fibromatosis first described substantial quite earlier in 1743 by the French physician François Gigot de la Peyronie (1678-1747) [2,5-12]. Histopathological findings in plantar fibromatosis reveal similar findings to those in palmar fibromatosis [13]. In the literature, it has been proposed for palmar fibromatosis that growth factors, such as platelet-derived growth factor and transforming growth factor-beta, free oxidized radicals, increased levels of plasminogen activator enzymes, and expression of Ki-67 antigen contribute the etiology, and it was found that the number of androgen receptors in specimens of palmar fibromatoses was considerably higher than in normal palmar fascia [14-19]. Noted that expression of the Ki-67 antigen plays an important role in detection of malignancies [20]. For the palmar fibromatosis, family history probably has the strongest influence on the age at time of first surgery compared to environmental factors, followed by male sex, and the percentage of familial cases decreased with age of onset from 55% in patients aged 40-49 years to 17% in patientsaged80 years and older, and men are upto 15 times more likely to suffer from this disease but during the 8th and 9th decade of life the ratio between affected men and women is equal [21,22]. Moreover, palmar fibromatosis is more frequently observed in the white Caucasian and Nordic race than in Africa or Asia [23]. Noted that the incidence of palmar fibromatosis in elderly men is reported to be up to 25.3% in Australia [24], up to 28.9% in Ireland [25], and up to 13.75% in England [26]. The differential diagnosis of plantar fibromatosis should include
足底纤维瘤病是一种罕见的良性、增生性、局部侵袭性足底肌腱膜(即筋膜)疾病(图1A)，病因不明，属于腹外硬纤维瘤之一。1894年，德国医生Georg Ledderhose(1855-1925)首次描述了足底纤维瘤，并伴有高复发率[1-3]。在病因方面，据报道，糖尿病、体重过轻、癫痫、酗酒和吸烟的患者最常发生此病，并且高达19.1%的病例也有家族史[2,4]。在2至83岁的所有年龄段(N=178)均可观察到该病的发生，但在没有明显性别相关差异的情况下，尤其发生在生命的第4和第5个10岁(178例患者中男性为51.7%，女性为48.3%)，据报道，双侧受累的病例占20-50%[2,4]。5-21.3%的病例可与手掌纤维瘤病(图2 - d)相关(图2 - d)，早在1831年，法国医生Baron Guillaume Dupuytren(1777 - 1835)首次描述了这种疾病，也可与指间近端手指关节的纤维性皮下结节(即指节垫)相关(图3)，1904年，英国医生SirArchibald Edward Garrod(1857-1936)首次描述了这种疾病。在1-3%的阴茎纤维瘤病病例中，法国医生franois Gigot de la Peyronie(1678-1747)在1743年首次描述了这种疾病[2,5-12]。足底纤维瘤病的组织病理学表现与掌部纤维瘤病相似[13]。文献中提出掌纤维瘤病的病因与血小板源性生长因子、转化生长因子- β、游离氧化自由基、纤溶酶原激活酶水平升高、Ki-67抗原表达等生长因子有关，并发现掌纤维瘤标本中雄性激素受体的数量明显高于正常掌筋膜[14-19]。注意到Ki-67抗原的表达在恶性肿瘤的检测中起着重要的作用[20]。掌纤维瘤病,家族史可能影响最强的年龄第一次手术相比,环境因素,其次是男性,和家族病例的比例从55%下降与发病的年龄在40至49岁的患者17% patientsaged80岁及以上,男性高达15倍,患有这种疾病,而是在8日和9日十年的生活受影响的男性和女性之间的比率=(21、22)。此外，与非洲或亚洲相比，掌肌瘤病在白种人和北欧人种中更为常见[23]。值得注意的是，据报道，老年男性掌纤维瘤病的发病率在澳大利亚高达25.3%[24]，在爱尔兰高达28.9%[25]，在英国高达13.75%[26]。足底纤维瘤病的鉴别诊断应包括狭窄性腱鞘炎、踝关节神经节囊肿伴足底内侧神经卡压(即跖管综合征)(图4A-B)、其他导致足底指神经卡压的情况，如原发性莫顿神经瘤(图5A-C)或继发性创伤后/术后神经瘤(图6A-C)、足底筋膜炎或破裂，伴或不伴足底跟骨刺(图7与图8相比)。伴或不伴Haglund氏外生性增生的足跟滑囊炎(图7与图8对比)、无菌性骨坏死如Köhler病(图9)或其他良恶性病变(图10)，包括纤维肉瘤[27,28]。迷你回顾
{"title":"Ledderhose’s Disease-What do We Know and What do We not know","authors":"I. Schmidt","doi":"10.36876/smmd.1033","DOIUrl":"https://doi.org/10.36876/smmd.1033","url":null,"abstract":"Plantar fibromatosis of the foot is a rare benign, hyperproliferative, and local aggressive disease of the plantar aponeurosis (i.e. fascia) (Figure 1A) of unknown etiology and included among the extra-abdominal desmoids tumors, this entity was first described in 1894 bythe German physician Georg Ledderhose (1855-1925), and it is accompanied by a high recurrence rate [1-3]. Regarding etiology, it has been described to be most frequent in patients with diabetes, low body weight, epilepsy, alcohol abuse, and smoking, and a familial history in up to 19.1% of cases is observed as well [2,4]. Occurrence is observed at all ages ranging from 2 to 83 years (N=178), but especially in the 4th and 5th decade of life in the absence of significant sex-related differences (51.7% male vs. 48.3% female in 178 patients), and bilateral involvement is reported to be 20-50% of cases [2,4]. It can be associated in 5-21.3% of cases with the palmar fibromatosis of the hand (Figure 2A-D) first described quite earlier in 1831by the French physician Baron Guillaume Dupuytren (17771835) which can also be associated with the fibrous subcutaneous nodules (i.e. knuckle pads) upon the proximal interphalangeal finger joints (Figure 3) first described in1904 by the British physician SirArchibald Edward Garrod (1857-1936), and in 1-3% of cases with the penile fibromatosis first described substantial quite earlier in 1743 by the French physician François Gigot de la Peyronie (1678-1747) [2,5-12]. Histopathological findings in plantar fibromatosis reveal similar findings to those in palmar fibromatosis [13]. In the literature, it has been proposed for palmar fibromatosis that growth factors, such as platelet-derived growth factor and transforming growth factor-beta, free oxidized radicals, increased levels of plasminogen activator enzymes, and expression of Ki-67 antigen contribute the etiology, and it was found that the number of androgen receptors in specimens of palmar fibromatoses was considerably higher than in normal palmar fascia [14-19]. Noted that expression of the Ki-67 antigen plays an important role in detection of malignancies [20]. For the palmar fibromatosis, family history probably has the strongest influence on the age at time of first surgery compared to environmental factors, followed by male sex, and the percentage of familial cases decreased with age of onset from 55% in patients aged 40-49 years to 17% in patientsaged80 years and older, and men are upto 15 times more likely to suffer from this disease but during the 8th and 9th decade of life the ratio between affected men and women is equal [21,22]. Moreover, palmar fibromatosis is more frequently observed in the white Caucasian and Nordic race than in Africa or Asia [23]. Noted that the incidence of palmar fibromatosis in elderly men is reported to be up to 25.3% in Australia [24], up to 28.9% in Ireland [25], and up to 13.75% in England [26]. The differential diagnosis of plantar fibromatosis should include","PeriodicalId":132433,"journal":{"name":"SM Musculoskeletal Disorders","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117134463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：